|
IL36670A
(en)
|
1971-04-21 |
1974-09-10 |
Sela M |
Therapeutic basic copolymers of amino acids
|
|
FR2459619B1
(fr)
|
1979-06-26 |
1983-07-29 |
Agronomique Inst Nat Rech |
Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
|
|
US4350156A
(en)
|
1980-05-29 |
1982-09-21 |
Japan Foundation For Artificial Organs |
Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
|
|
US4455256A
(en)
|
1981-05-05 |
1984-06-19 |
The Regents Of The University Of California |
Bone morphogenetic protein
|
|
US5599309A
(en)
|
1993-03-24 |
1997-02-04 |
Owen Mumford Limited |
Injection devices
|
|
IL113812A
(en)
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
|
US5631347A
(en)
|
1995-06-07 |
1997-05-20 |
Eli Lilly And Company |
Reducing gelation of a fatty acid-acylated protein
|
|
DE19543737A1
(de)
|
1995-11-24 |
1997-05-28 |
Hoechst Ag |
Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
|
|
US6214791B1
(en)
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
IL119989A0
(en)
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
IL141021A0
(en)
|
1998-07-23 |
2002-02-10 |
Yeda Res & Dev |
Treatment of autoimmune conditions with copolymer 1 and related copolymers
|
|
WO2000005249A2
(en)
|
1998-07-23 |
2000-02-03 |
The President And Fellows Of Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
DK2239269T3
(da)
|
1998-09-25 |
2013-04-29 |
Yeda Res & Dev |
Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
WO2000020010A1
(en)
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
AU775073C
(en)
|
1998-11-12 |
2007-05-03 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
|
|
IL150895A0
(en)
|
2000-02-18 |
2003-02-12 |
Teva Pharma |
Oral, nasal and pulmonary formulations of copolymer-1
|
|
US7022663B2
(en)
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
HUP0302333A3
(en)
|
2000-06-05 |
2005-07-28 |
Teva Pharma |
The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
DE10158009A1
(de)
*
|
2001-11-21 |
2003-05-28 |
Begerow E Gmbh & Co |
Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen
|
|
US7429374B2
(en)
|
2001-12-04 |
2008-09-30 |
Teva Pharmaceutical Industries, Ltd. |
Process for the measurement of the potency of glatiramer acetate
|
|
CA2411786C
(en)
|
2002-11-13 |
2009-01-27 |
Brantford Chemicals Inc. |
A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
|
|
US7777006B2
(en)
|
2002-12-31 |
2010-08-17 |
Csl Behring L.L.C. |
Method for purification of alpha-1-antitrypsin
|
|
RU2339397C2
(ru)
|
2003-01-21 |
2008-11-27 |
Йеда Рисерч Энд Дивелопмент Ко.Лтд. |
Сор1 для лечения воспалительных заболеваний кишечника
|
|
US20070037740A1
(en)
|
2003-03-04 |
2007-02-15 |
Irit Pinchasi |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
WO2004103297A2
(en)
|
2003-05-14 |
2004-12-02 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
|
|
BRPI0412735A
(pt)
|
2003-07-18 |
2006-09-26 |
Baxter Int |
métodos para a fabricação, uso e composição de partìculas esféricas pequenas preparadas mediante a separação de fase controlada
|
|
JP2007509981A
(ja)
|
2003-10-31 |
2007-04-19 |
テバ ファーマシューティカル インダストリーズ リミティド |
薬物デリバリー用ナノ粒子
|
|
WO2005063800A2
(en)
|
2003-12-31 |
2005-07-14 |
F. Hoffmann-La Roche Ag |
Peptide synthesis using decanting filter
|
|
EP1778286A4
(en)
|
2004-03-03 |
2009-04-08 |
Teva Pharma |
COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
|
|
US20060194725A1
(en)
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
US7655221B2
(en)
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
EP1796710A4
(en)
|
2004-09-02 |
2010-05-26 |
Teva Pharma |
THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
|
|
HRP20160455T1
(hr)
|
2004-09-09 |
2016-07-15 |
Yeda Research And Development Co., Ltd. |
Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
|
|
ZA200702591B
(en)
|
2004-09-09 |
2009-03-25 |
Teva Pharma |
Process for preparation of mixtures of polypeptides using purified hydrobromic acid
|
|
AR052321A1
(es)
|
2004-10-29 |
2007-03-14 |
Sandoz Ag |
Procesos para la preparacion de un polipeptido
|
|
JP2008528589A
(ja)
|
2005-02-02 |
2008-07-31 |
テバ ファーマシューティカル インダストリーズ リミティド |
水素化分解を用いてポリペプチド混合物を作成する方法
|
|
US20100167983A1
(en)
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
WO2006089164A1
(en)
|
2005-02-17 |
2006-08-24 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
CA2606194A1
(en)
|
2005-04-25 |
2006-11-02 |
Yeda Research And Development Company |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
|
US20070059798A1
(en)
|
2005-09-09 |
2007-03-15 |
Alexander Gad |
Polypeptides useful for molecular weight determinations
|
|
WO2007081975A2
(en)
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
US20080118553A1
(en)
|
2006-06-12 |
2008-05-22 |
Anton Frenkel |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
JP2009542864A
(ja)
|
2006-07-05 |
2009-12-03 |
モメンタ ファーマシューティカルズ インコーポレイテッド |
コポリマー１の調製のための改良法
|
|
CN100569282C
(zh)
|
2006-10-13 |
2009-12-16 |
俞嘉林 |
注射用骨肽冻干剂及其制备方法
|
|
US8753833B2
(en)
|
2007-06-21 |
2014-06-17 |
Momenta Pharmaceuticals, Inc. |
Copolymer assay
|
|
US8993722B2
(en)
|
2007-07-31 |
2015-03-31 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
|
CA2702437C
(en)
|
2007-11-28 |
2013-06-25 |
Teva Pharmaceutical Industries Ltd. |
Method of delaying the onset of clinically definite multiple sclerosis
|
|
US8030297B2
(en)
|
2008-05-14 |
2011-10-04 |
Otonomy, Inc. |
Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
|
|
US8323685B2
(en)
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
|
CA2697570C
(en)
|
2009-07-15 |
2011-11-01 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
NZ598661A
(en)
*
|
2009-08-20 |
2013-02-22 |
Yeda Res & Dev |
Low frequency glatiramer acetate therapy
|
|
ITMI20092069A1
(it)
|
2009-11-25 |
2011-05-26 |
Biofer Spa |
Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro.
|
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
CA2814500A1
(en)
|
2010-10-11 |
2012-04-19 |
Teva Pharmaceutical Industries Ltd |
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
|
|
CA2827275A1
(en)
|
2011-02-14 |
2012-09-20 |
Usv Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
|
US8575198B1
(en)
*
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
|
HK1200274A1
(en)
|
2011-10-10 |
2015-08-07 |
Teva Pharmaceutical Industries Ltd. |
Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
|
|
WO2014008400A2
(en)
*
|
2012-07-06 |
2014-01-09 |
3-D Matrix, Inc. |
Fill-finish process for peptide solutions
|
|
HK1213830A1
(zh)
|
2012-10-10 |
2016-07-15 |
Teva Pharmaceutical Industries Ltd. |
用於预测醋酸格拉替雷临床反应的生物标志物
|
|
MX2015008754A
(es)
|
2013-01-04 |
2016-04-11 |
Teva Pharma |
Caracterizacion de un medicamento relacionado con acetato de glatiramer.
|
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
|
US20140271630A1
(en)
|
2013-03-12 |
2014-09-18 |
Teva Pharmaceutical Industries, Ltd. |
Rituximab induction therapy followed by glatiramer acetate therapy
|
|
CN103169670B
(zh)
*
|
2013-03-22 |
2016-07-06 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷微球及其制备方法
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|